EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies

Alvaro Prados-Carmona, Husein Husein-ElAhmed iD, Francisco José Navarro-Triviño iD, Ricardo Ruiz-Villaverde iD

International Journal of Molecular Sciences · 27.11.2025 · 26 (23) · 11487

DOI: 10.3390/ijms262311487 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.11.2025. Verfasst von Alvaro Prados-Carmona und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario San Cecilio, 18016 Granada, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis is the most prevalent chronic inflammatory skin disease, posing a significant individual and healthcare burden. Traditionally managed with topical agents and broad immunosuppressants, the treatment landscape has shifted significantly in recent years. This review explores the transition from immunopathogenic understanding to personalized treatment strategies through advanced systemic therapies. We provide a thorough description of the current therapeutic arsenal, including approved monoclonal antibodies and Janus kinase (JAK) inhibitors, as well as experimental agents under clinical investigation. Key cytokines and receptors implicated in type 2 inflammation are explored alongside relevant intracellular signaling pathways. Special attention has been given to literature published from 2015 onwards. By synthesizing the latest scientific and clinical knowledge, this review aims to provide clinicians with practical guidance for navigating the evolving landscape of atopic dermatitis management and improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansJanus Kinase InhibitorsAntibodies, MonoclonalSignal TransductionCytokines

Stichwörter der Autor:innen

atopic dermatitisimmunologypathophysiologyreviewsystemic treatment

Substanzen

Janus Kinase InhibitorsAntibodies, MonoclonalCytokines

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitario San Cecilio, 18016 Granada, Spain.
  • Instituto Biosanitario de Granada, ibs.Granada, 18012 Granada, Spain.
  • Escuela Internacional de Posgrado, Universidad de Granada, 18012 Granada, Spain.
  • Department of Dermatology, Hospital de Baza, 18800 Granada, Spain.
  • Unit of Contact Eczema and Immunoallergic Diseases, Hospital Universitario San Cecilio, 18016 Granada, Spain.
  • Department of Medicine, University of Granada, 18016 Granada, Spain.

ORCID-Profile: Husein Husein-ElAhmed, Francisco José Navarro-Triviño, Ricardo Ruiz-Villaverde

Zitieren

APA

Prados-Carmona, A., Husein-ElAhmed, H., Navarro-Triviño, F. J., & Ruiz-Villaverde, R. (2025). From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies. International Journal of Molecular Sciences, 26(23), 11487. https://doi.org/10.3390/ijms262311487

Vancouver

Prados-Carmona A, Husein-ElAhmed H, Navarro-Triviño FJ, Ruiz-Villaverde R. From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies. International Journal of Molecular Sciences. 2025;26(23):11487. doi:10.3390/ijms262311487

BibTeX
@article{PradosCarmona2025,
  author = {Prados-Carmona, Alvaro and Husein-ElAhmed, Husein and Navarro-Triviño, Francisco José and Ruiz-Villaverde, Ricardo},
  title = {From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {23},
  pages = {11487},
  doi = {10.3390/ijms262311487}
}
Kostenlos starten →